公开(公告)号：US11932693B2

公开(公告)日：2024-03-19

申请号：US18315686

申请日：2023-05-11

Applicant: BioNTech SE ,  Genmab A/S

Inventor： Ugur Sahin ,  Sina Fellermeier-Kopf ,  Friederike Gieseke ,  Karsten Beckmann ,  Claudia Paulmann ,  Alexander Muik ,  Ivan Kuzmanov ,  Esther Cornelia Wilhelmina Breij ,  Patricia Garrido Castro ,  Jordan Blum ,  Lars Guelen ,  Joost Neijssen ,  Bart-Jan De Kreuk ,  Richard Hibbert ,  Janine Schuurman ,  Aran Frank Labrijn

IPC: C07K16/28

CPC classification number: C07K16/2818 ,  C07K2317/24 ,  C07K2317/92

Abstract: The present disclosure relates to antibodies having the ability to bind to the immune checkpoint protein programmed death-1 (PD-1), such as human PD-1, or nucleic acids encoding such antibodies, wherein the antibodies comprise modifications in the Fc region eliminating or reducing a Fc-mediated effector function of the antibodies. The present disclosure also relates to compositions or kits comprising said antibodies or nucleic acids, as well as to the use of these antibodies or nucleic acids or compositions in the field of medicine, preferably in the field of immunotherapy, e.g., for the treatment of cancers. The present invention further relates to methods for inducing an immune response in a subject comprising providing to the subject an antibody of the present disclosure or one or more nucleic acids encoding such an antibody, or a composition comprising said antibody or nucleic acids.

公开(公告)号：US09663578B2

公开(公告)日：2017-05-30

申请号：US14317600

申请日：2014-06-27

Applicant: GENMAB A/S

Inventor： Edward Norbert Van Den Brink ,  Paul Parren ,  Jan Van De Winkel ,  Aran Frank Labrijn ,  Frank Everhardus Martinus Rebers ,  Esther Cornelia Wilhelmina Breij

IPC: A61K39/395 ,  C07K16/28 ,  A61K39/00

CPC classification number: C07K16/283 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/30 ,  C07K2317/33 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/92

Abstract: Isolated monoclonal antibodies which bind to human CD32b and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.